From early acid-driven magnesium-based micromotors for gastric ulcer treatment, which utilize gastric acid to generate hydrogen bubbles for propulsion and local drug release [43], to the emergence of multifunctional MNMs today (e.g., bacteria-driven microrobots targeting gut microbiota for IBD therapy [44]), these advancements highlight the potential of MNMs to improve drug bioavailability, reduce systemic toxicity, and enhance patient compliance, holding promise to revolutionize the treatment of digestive system diseases
It promotes neuronal differentiation, development, and survival, and plays a key role in neurogenesis, synaptogenesis, and synaptic plasticity [83, 84]
Insurance companies often impose their own BMI requirements (sometimes 35 or higher), which are stricter than FDA guidance
The overwhelming majority of employers cover at least some GLP-1 medications for diabetes